Document Detail

Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies.
MedLine Citation:
PMID:  20438756     Owner:  NLM     Status:  In-Process    
Cardiac hypertrophy can be defined as an increase in heart mass. Pathological cardiac hypertrophy (heart growth that occurs in settings of disease, e.g. hypertension) is a key risk factor for heart failure. Pathological hypertrophy is associated with increased interstitial fibrosis, cell death and cardiac dysfunction. In contrast, physiological cardiac hypertrophy (heart growth that occurs in response to chronic exercise training, i.e. the 'athlete's heart') is reversible and is characterized by normal cardiac morphology (i.e. no fibrosis or apoptosis) and normal or enhanced cardiac function. Given that there are clear functional, structural, metabolic and molecular differences between pathological and physiological hypertrophy, a key question in cardiovascular medicine is whether mechanisms responsible for enhancing function of the athlete's heart can be exploited to benefit patients with pathological hypertrophy and heart failure. This review summarizes key experimental findings that have contributed to our understanding of pathological and physiological heart growth. In particular, we focus on signaling pathways that play a causal role in the development of pathological and physiological hypertrophy. We discuss molecular mechanisms associated with features of cardiac hypertrophy, including protein synthesis, sarcomeric organization, fibrosis, cell death and energy metabolism and provide a summary of profiling studies that have examined genes, microRNAs and proteins that are differentially expressed in models of pathological and physiological hypertrophy. How gender and sex hormones affect cardiac hypertrophy is also discussed. Finally, we explore how knowledge of molecular mechanisms underlying pathological and physiological hypertrophy may influence therapeutic strategies for the treatment of cardiovascular disease and heart failure.
Bianca C Bernardo; Kate L Weeks; Lynette Pretorius; Julie R McMullen
Related Documents :
17556886 - Echocardiographic left ventricular hypertrophy in hypertension: marker for future event...
2944766 - Physiological adaptation of the heart to pathological overloading.
12665256 - Preischemic administration of ribose to delay the onset of irreversible ischemic injury...
3158686 - Right ventricular myocardial infarction in patients with chronic lung disease: possible...
25274496 - Transapical myectomy and surgical cryoablation for refractory ventricular tachycardia d...
7747856 - Cardiac arrest and resuscitation of a 6-month old achondroplastic baby undergoing neuro...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-05-12
Journal Detail:
Title:  Pharmacology & therapeutics     Volume:  128     ISSN:  1879-016X     ISO Abbreviation:  Pharmacol. Ther.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7905840     Medline TA:  Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  191-227     Citation Subset:  IM    
Copyright Information:
2010 Elsevier Inc. All rights reserved.
Cardiac Hypertrophy Laboratory, Baker IDI Heart & Diabetes Institute, Melbourne, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of acute dieldrin exposure on neurotransmitters and global gene transcription in largemouth ...
Next Document:  Sigma receptors: potential targets for a new class of antidepressant drug.